IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
UP-0518534
(2006-09-08)
|
| 등록번호 |
US-7687479
(2010-04-23)
|
|
발명자
/ 주소 |
- Sasisekharan, Ram
- Venkataraman, Ganesh
- Shriver, Zachary
- Liu, Dongfang
- Sundaram, Mallikarjun
- Qi, Yiwei
|
| 출원인 / 주소 |
- Massachusetts Institute of Technology
|
| 대리인 / 주소 |
Wolf, Greenfield & Sacks, P.C.
|
| 인용정보 |
피인용 횟수 :
4 인용 특허 :
85 |
초록
The invention relates, in part, to methods and products related to producing low molecular weight heparin.
대표청구항
▼
We claim: 1. A method of producing a low molecular weight heparin (LMWH) preparation comprising: providing a second fraction of LMWH obtained by salt precipitation of a glycosaminoglycan (GAG) containing sample in a solvent that produces a first high molecular weight fraction and the second fractio
We claim: 1. A method of producing a low molecular weight heparin (LMWH) preparation comprising: providing a second fraction of LMWH obtained by salt precipitation of a glycosaminoglycan (GAG) containing sample in a solvent that produces a first high molecular weight fraction and the second fraction of LMWH, wherein the second fraction of LMWH is separated from the first high molecular weight fraction, and processing the separated second fraction to produce a concentrated LMWH preparation, wherein the processing is enzymatic digestion of the second fraction. 2. The method of claim 1, wherein the GAG containing sample is unfractionated heparin. 3. The method of claim 1, wherein the salt precipitation is performed with a salt of divalent cations and weak anions. 4. The method of claim 3, wherein the salt of the divalent cation is selected from the group consisting of barium, calcium, magnesium, strontium, copper, nickel, cadmium, zinc, mercury, beryllium, nickel, palladium, platinum, iron and tin. 5. The method of claim 3, wherein the divalent cation is calcium. 6. The method of claim 1, wherein the salt is calcium acetate. 7. The method of claim 1, wherein the precipitation occurs at a temperature in the range of 20° C. to 1° C. 8. The method of claim 7, wherein the precipitation occurs at a temperature in the range of 15° C. to 5° C. 9. The method of claim 1, wherein the solvent is selected from H2O, H2O and ethanol, ethanol, H2O and acetone, and acetone. 10. The method of claim 9, wherein the solvent is H2O and ethanol. 11. The method of claim 10, wherein the solvent has an H2O:ethanol ratio of 65:35 to 35:65. 12. The method of claim 11, wherein the solvent has an H2O:ethanol ratio of 55:45 to 45:55. 13. The method of claim 1, wherein the second fraction of LMWH is contained in the supernatants. 14. The method of claim 1, wherein the average molecular weight of the second fraction is 8000 Da or less than 8000 Da. 15. The method of claim 1, wherein the average molecular weight of the second fraction is less than 8000 Da. 16. The method of claim 1, wherein the second fraction has at least 60% of the molecules having a molecular weight of less than 8000 Da. 17. The method of claim 1, wherein the second fraction LWMH is digested with heparinase III. 18. The method of claim 17, further comprising purifying or separating the digested second LWMH fraction. 19. The method of claim 17, further comprising precipitating the digested second LMWH fraction. 20. The method of claim 18, further comprising formulating the purified LWMH fraction with a pharmaceutical carrier. 21. The method of claim 1, wherein the second fraction LWMH is digested with a modified heparinase III, wherein the modified heparinase III comprises a polypeptide having the amino acid sequence of the mature peptide of SEQ ID NO: 2, wherein at least one histidine residue selected from the group consisting of His36, His105, His110, His139, His152, His225, His234, His241, His424, His469and His539has been substituted. 22. The method of claim 21, further comprising purifying or separating the digested second LWMH fraction. 23. The method of claim 21, further comprising precipitating the digested second LMWH fraction. 24. The method of claim 22, further comprising formulating the purified LWMH fraction with a pharmaceutical carrier. 25. A method of producing a low molecular weight heparin (LMWH) comprising: performing a salt precipitation of a glycosaminoglycan (GAG) containing sample in a solvent to produce a first high molecular weight fraction, and a second fraction of LMWH, separating the first high molecular weight fraction from the second fraction of LMWH, and processing the separated second fraction to produce a concentrated LMWH, wherein the processing is enzymatic digestion of the second fraction. 26. The method of claim 25, wherein the method further comprises precipitation of the second fraction of LMWH with a solvent. 27. The method of claim 26, wherein the solvent is selected from ethanol and the combination of H2O and ethanol. 28. The method of claim 25, wherein the GAG containing sample is unfractionated heparin. 29. The method of claim 25, wherein the salt precipitation is performed with a salt of divalent cations and weak anions. 30. The method of claim 29, wherein the salt of the divalent cation is selected from the group consisting of barium, calcium, magnesium, strontium, copper, nickel, cadmium, zinc, mercury, beryllium, nickel, palladium, platinum, iron and tin. 31. The method of claim 29, wherein the divalent cation is calcium. 32. The method of claim 25, wherein the salt is calcium acetate. 33. The method of claim 25, wherein the precipitation occurs at a temperature in the range of 20° C. to 1° C. 34. The method of claim 33, wherein the precipitation occurs at a temperature in the range of 15° C. to 5° C. 35. The method of claim 25, wherein the solvent is selected from H2O, H2O and ethanol, ethanol, H2O and acetone, and acetone. 36. The method of claim 35, wherein the solvent is H2O and ethanol. 37. The method of claim 36, wherein the solvent has an H2O: ethanol ratio of 65:35 to 35:65. 38. The method of claim 37, wherein the solvent has an H2O: ethanol ratio of 55:45 to 45:55. 39. The method of claim 25, wherein the second fraction of LMWH is contained in the supernatant. 40. The method of claim 25, wherein the average molecular weight of the second fraction is 8000 Da or less than 8000 Da. 41. The method of claim 25, wherein the average molecular weight of the second fraction is less than 8000 Da. 42. The method of claim 25, wherein the second fraction has at least 60% of the molecules having a molecular weight of less than 8000 Da. 43. The method of claim 25, wherein the second fraction LWMH is digested with heparinase III. 44. The method of claim 43, further comprising purifying or separating the digested second LWMH fraction. 45. The method of claim 44, further comprising formulating the purified LWMH fraction with a pharmaceutical carrier. 46. The method of claim 43, further comprising precipitating the digested second LMWH fraction. 47. The method of claim 25, wherein the second fraction LWMH is digested with a modified heparinase III, wherein the modified heparinase III comprises a polypeptide having the amino acid sequence of the mature peptide of SEQ ID NO: 2, wherein at least one histidine residue selected from the group consisting of His36, His105, His110, His139, His152, His225, His234, His241, His424, His469and His539has been substituted. 48. The method of claim 47, further comprising purifying or separating the digested second LWMH fraction. 49. The method of claim 48, further comprising formulating the purified LWMH fraction with a pharmaceutical carrier. 50. The method of claim 47, further comprising precipitating the digested second LMWH fraction.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.